Literature DB >> 28260087

Knockdown of PARP6 or survivin promotes cell apoptosis and inhibits cell invasion of colorectal adenocarcinoma cells.

Haipeng Wang1, Shengguo Li1, Xishun Luo1, Zhike Song1, Xiangkai Long1, Xijia Zhu1.   

Abstract

Colorectal adenocarcinoma is the third most common cancer worldwide. PARP6, a novel member of the poly(ADP-ribose) polymerases (PARPs) and survivin, a member of the family of inhibitor of apoptosis (IAP) proteins are associated with a poor prognosis in various types of cancers. However, limited evidence exists regarding the interaction between PARP6 and survivin in colorectal adenocarcinoma. In the present study, we used the paired samples of 20 patients with colorectal adenocarcinoma to detect the expression of PARP6 and survivin in both tumor and adjacent normal colorectal mucosa. Their interaction and roles in cell viability, cell cycle, cell apoptosis and cell invasion were further investigated. Our results showed that both PARP6 and survivin exhibited higher expression in colorectal adenocarcinoma tissues and SW620 cells when compared with levels in adjacent non-tumor tissues and a normal colon cell line FHC. Co-immunoprecipitation assay showed that a significant correlation existed between PARP6 and survivin. We also showed that sole treatment of PARP6 siRNA or survivin siRNA partially inhibited the cell survival and invasion, induced cell G0/G1 arrest, and cell apoptosis at the early and late stages. The combined treatment of PARP6 siRNA and survivin siRNA suppressed the cell survival and cell invasion, further induced cell cycle phase G0/G1 arrest, and cell apoptosis at the early and late stages. Taken together, knockdown of PARP6 or survivin promotes cell apoptosis and inhibits the cell invasion of colorectal adenocarcinoma cells. A significant correlation exists between PARP6 and survivin, and both are promising targets for the development of new strategies for the diagnosis and treatment of advanced or metastatic colorectal adenocarcinoma.

Entities:  

Mesh:

Substances:

Year:  2017        PMID: 28260087     DOI: 10.3892/or.2017.5441

Source DB:  PubMed          Journal:  Oncol Rep        ISSN: 1021-335X            Impact factor:   3.906


  8 in total

1.  Suppression of Long Noncoding RNA SNHG1 Inhibits the Development of Hypopharyngeal Squamous Cell Carcinoma via Increasing PARP6 Expression.

Authors:  Qian Chen; Xiao He; Bin Li; Jingjing Chen; Xuxia Tang
Journal:  Evid Based Complement Alternat Med       Date:  2022-07-05       Impact factor: 2.650

2.  Alternative splicing redefines landscape of commonly mutated genes in acute myeloid leukemia.

Authors:  Osvaldo D Rivera; Michael J Mallory; Mathieu Quesnel-Vallières; Rakesh Chatrikhi; David C Schultz; Martin Carroll; Yoseph Barash; Sara Cherry; Kristen W Lynch
Journal:  Proc Natl Acad Sci U S A       Date:  2021-04-13       Impact factor: 11.205

3.  Cancer-associated fibroblasts contribute to cisplatin resistance by modulating ANXA3 in lung cancer cells.

Authors:  Limin Wang; Xueqin Li; Yinghui Ren; Hua Geng; Qicheng Zhang; Limin Cao; Zhaowei Meng; Xiang Wu; Meilin Xu; Ke Xu
Journal:  Cancer Sci       Date:  2019-04-09       Impact factor: 6.716

Review 4.  Research Advances in the Role of the Poly ADP Ribose Polymerase Family in Cancer.

Authors:  Huanhuan Sha; Yujie Gan; Renrui Zou; Jianzhong Wu; Jifeng Feng
Journal:  Front Oncol       Date:  2021-12-16       Impact factor: 6.244

Review 5.  Functional roles of ADP-ribosylation writers, readers and erasers.

Authors:  Ping Li; Yushuang Lei; Jia Qi; Wanqin Liu; Kai Yao
Journal:  Front Cell Dev Biol       Date:  2022-08-11

6.  Impaired Bestrophin Channel Activity in an iPSC-RPE Model of Best Vitelliform Macular Dystrophy (BVMD) from an Early Onset Patient Carrying the P77S Dominant Mutation.

Authors:  Arnau Navinés-Ferrer; Sheila Ruiz-Nogales; Rafael Navarro; Esther Pomares
Journal:  Int J Mol Sci       Date:  2022-07-04       Impact factor: 6.208

Review 7.  The Role of PARPs in Inflammation-and Metabolic-Related Diseases: Molecular Mechanisms and Beyond.

Authors:  Yueshuang Ke; Chenxin Wang; Jiaqi Zhang; Xiyue Zhong; Ruoxi Wang; Xianlu Zeng; Xueqing Ba
Journal:  Cells       Date:  2019-09-06       Impact factor: 6.600

8.  ZC3HAV1 promotes the proliferation and metastasis via regulating KRAS in pancreatic cancer.

Authors:  Wei Huang; Hao Hua; Guoliang Xiao; Xianjin Yang; Qin Yang; Lu Jin
Journal:  Aging (Albany NY)       Date:  2021-07-28       Impact factor: 5.682

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.